ArticleFrontiers in oncology2018

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

Prajwal Boddu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.